| | 1038915-60-4 Basic information More.. |
| Product Name: | Niraparib | | Synonyms: | MK-4827,(S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxaMide;Niraparib;2-[4-((3S)-3-Piperidinyl)phenyl]-2H-indazole-7-carboxamide;MK4827 (Niraparib);2H-Indazole-7-carboxamide, 2-[4-(3S)-3-piperidinylphenyl]-;(S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide hydrocholoride;2-[4-(3S)piperidin-3-ylphenyl]-2H-indazol-7-carboxamide;2-[4-[(3s)-piperidin-3-yl]phenyl]indazole-7-carboxamide | | CAS: | 1038915-60-4 | | MF: | C19H20N4O | | MW: | 320.39 | | EINECS: | | | Mol File: | 1038915-60-4.mol |  |
Use
The synthesis and initial pharmacology of niraparib have been published. Niraparib has affinity for PARP 1 and 2 inhibition (IC50 = 3.8 and 2.1 nM, respectively) and inhibits the proliferation of cancer cells with mutant BRCA1 and BRCA2 with IC50 values in the 10100 nM range in vitro. Niraparib demonstrated efficacy as a single agent in a xenograft model of BRCA1-deficient cancer. Niraparib has also been reported to act as a preclinical radiosensitiser and has entered into clinical oncology trials.
- Niraparib USP/EP/BP
-
- US $1.10 / g
- 2025-11-18
- CAS:1038915-60-4
- Min. Order: 1g
- Purity: 99.9%
- Supply Ability: 100 Tons min
- Niraparib
-
- US $55.00-113.00 / mg
- 2025-11-10
- CAS:1038915-60-4
- Min. Order:
- Purity: 99.85%
- Supply Ability: 10g
- Niraparib
-
- US $0.00-0.00 / mg
- 2025-09-25
- CAS:1038915-60-4
- Min. Order: 10mg
- Purity: 0.98
- Supply Ability: 10g
|
|
1038915-60-4
Recommend Suppliers |
|